Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

BACKGROUND: The approval of anti-programmed death ligand 1 (PD-L1) and anti-programmed death 1 agents has expanded treatment options for patients with locally advanced or metastatic urothelial carcinoma. Avelumab, a human monoclonal anti-PD-L1 antibody, has shown promising antitumour activity and sa...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Lancet Oncol
Главные авторы: Patel, Manish R, Ellerton, John, Infante, Jeffrey R, Agrawal, Manish, Gordon, Michael, Aljumaily, Raid, Britten, Carolyn D, Dirix, Luc, Lee, Keun-Wook, Taylor, Mathew, Schöffski, Patrick, Wang, Ding, Ravaud, Alain, Gelb, Arnold B, Xiong, Junyuan, Rosen, Galit, Gulley, James L, Apolo, Andrea B
Формат: Artigo
Язык:Inglês
Опубликовано: 2017
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7984727/
https://ncbi.nlm.nih.gov/pubmed/29217288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30900-2
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы